Keyword: Spark Therapeutics

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.

Intent to focus on the first -ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets.

The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.

Payers are now holding up Spark's $850,000 gene therapy as an example of how innovative drug developers can help payers afford pricey new treatments.

Roche picked up FDA approval in November for its hemophilia A drug Hemlibra (emicizumab)—and now it has taken a big step forward in Europe.

The numbers behind NICE's choice to endorse Strimvelis show just how tough it can be to make money from gene therapy.

There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.

Spark's pioneering Luxturna won FDA approval Tuesday to become the first gene therapy to target disease caused by a specific mutation.